A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Adalimumab (Primary) ; Methotrexate
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 25 Jul 2018 Results (n=577) evalauting the totality of safety findings from 7 clinical trials (NCT00048542, NCT00775437, NCT00690573, NCT01166282, NCT01251614, NCT00409682 and NCT00686374) published in the Journal of Pediatrics
- 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.